サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1193317

色素異常症治療市場：タイプ別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Pigmentation Disorder Treatment Market By Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 275 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
色素異常症治療市場：タイプ別、治療法別、流通チャネル別：世界の機会分析および産業予測、2021-2031年
出版日: 2022年11月01日
発行: Allied Market Research
ページ情報: 英文 275 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

色素異常症治療の世界市場は、2021年に7億9979万米ドル、2031年には12億2091万米ドルに達し、2022年から2031年にかけてCAGR4.3％で成長すると予測されています。

色素異常症は、皮膚組織の異常であり、プライマリーケア診療で診断、評価、治療が可能です。皮膚の色は、メラニン色素によって引き起こされます。皮膚細胞の一種であるメラノサイトがこれを産生します。皮膚の色素障害は、様々な病状によってもたらされる可能性があります。特に、肝斑、浅黒い肌、白斑などは、皮膚の変色を引き起こす可能性のある疾患です。白斑、白色粃糠疹、癜風、炎症後色素沈着は、すべて色素沈着の状態です。

色素異常症治療市場の成長を促進する主要な要因の1つは、色素異常症の有病率の増加です。例えば、2022年1月に発行されたIP Indian Journal of Clinical and Experimental Dermatologyによると、インドは白斑の有病率が約8.8％と最も高いとされています。さらに、ヘルスケア支出の増加、臨床研究および製品承認の数の増加が世界市場の成長に向けて貢献しています。例えば、2022年7月、Incyte Corporationは、12歳以上の成人および小児患者における非分節性白斑の局所治療用として、Opzelura（ルキソリチニブ）クリーム1.5%の承認を米国食品医薬品局（FDA）から取得しました。

さらに、色素沈着ヘルスケアへの取り組みの増加や健康問題に対する意識の高まりが、市場成長の原動力となることが期待されます。しかし、治療に伴う高額な費用が市場成長の妨げになることが予想されます。逆に、医療費の増加は、予測期間中に市場成長のための有利な機会を生み出すと予想されるもう1つの要因です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析
  • 特許情勢

第4章 色素異常症治療市場：タイプ別

  • 概要
    • 市場規模および予測
  • 白斑
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
    • 白斑色素異常症治療薬市場：タイプ別
      • セグメント別市場規模・予測：地域別
      • ノンセグメンテーション市場規模推移・予測：地域別
  • 肝斑
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 色素異常症治療市場：治療法別

  • 概要
    • 市場規模および予測
  • 副腎皮質ホルモン
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • カルシニューリン阻害剤
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 色素異常症治療市場：流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • ドラッグストア・小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • オンライン薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第7章 色素異常症治療市場： 地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米の市場規模・予測：タイプ別
      • 北米の白斑色素異常症治療市場：タイプ別
    • 北米の市場規模・予測：治療法別
    • 北米市場規模・予測：流通チャネル別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測：タイプ別
      • 欧州の白斑色素異常症治療市場：タイプ別
    • 欧州市場規模・予測：治療法別
    • 欧州市場規模・予測：流通チャネル別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他欧州
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：タイプ別
      • アジア太平洋地域の白斑色素異常症治療市場：タイプ別
    • アジア太平洋地域の市場規模・予測：治療法別
    • アジア太平洋地域の市場規模・予測：流通チャネル別
    • アジア太平洋地域の市場規模・予測：国別
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：タイプ別
      • LAMEAの白斑色素異常症治療市場：タイプ別
    • LAMEAの市場規模・予測：治療法別
    • LAMEAの市場規模・予測：流通チャネル別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Arcutis Biotherapeutics
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc
  • Incyte Corporation
  • Dermavant Science Inc.
  • Viatirs Inc.（Mylan N.V.）
  • Galderma SA
  • Obagi Cosmeceuticals LLC
  • Dr. Reddy's Laboratories Limited
  • Glenmark Pharmaceuticals Ltd
図表

LIST OF TABLES

  • TABLE 1. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. PIGMENTATION DISORDER TREATMENT MARKET, FOR VITILIGO, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. PIGMENTATION DISORDER TREATMENT MARKET FOR VITILIGO, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 5. PIGMENTATION DISORDER TREATMENT MARKET, FOR SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. PIGMENTATION DISORDER TREATMENT MARKET, FOR NON-SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. PIGMENTATION DISORDER TREATMENT MARKET, FOR MELASMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. PIGMENTATION DISORDER TREATMENT MARKET FOR MELASMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. PIGMENTATION DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. PIGMENTATION DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 12. PIGMENTATION DISORDER TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. PIGMENTATION DISORDER TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. PIGMENTATION DISORDER TREATMENT MARKET, FOR CALCINEURIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. PIGMENTATION DISORDER TREATMENT MARKET FOR CALCINEURIN INHIBITOR, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. PIGMENTATION DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. PIGMENTATION DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 19. PIGMENTATION DISORDER TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. PIGMENTATION DISORDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. PIGMENTATION DISORDER TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. PIGMENTATION DISORDER TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. PIGMENTATION DISORDER TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. PIGMENTATION DISORDER TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 25. PIGMENTATION DISORDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 32. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 33. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 34. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 36. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 50. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. UK PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 52. UK PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 53. UK PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 54. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 55. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 56. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 71. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 72. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 73. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 74. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 75. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 76. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 96. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
  • TABLE 102. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 103.ARCUTIS BIOTHERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 104.ARCUTIS BIOTHERAPEUTICS: OPERATING SEGMENTS
  • TABLE 105.ARCUTIS BIOTHERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 106.ARCUTIS BIOTHERAPEUTICS: NET SALES,
  • TABLE 107.ARCUTIS BIOTHERAPEUTICS: KEY STRATERGIES
  • TABLE 108.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 109.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
  • TABLE 110.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 111.ASTELLAS PHARMA INC.: NET SALES,
  • TABLE 112.ASTELLAS PHARMA INC.: KEY STRATERGIES
  • TABLE 113.BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT
  • TABLE 114.BAUSCH HEALTH COMPANIES INC: OPERATING SEGMENTS
  • TABLE 115.BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO
  • TABLE 116.BAUSCH HEALTH COMPANIES INC: NET SALES,
  • TABLE 117.BAUSCH HEALTH COMPANIES INC: KEY STRATERGIES
  • TABLE 118.INCYTE CORPORATION: COMPANY SNAPSHOT
  • TABLE 119.INCYTE CORPORATION: OPERATING SEGMENTS
  • TABLE 120.INCYTE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 121.INCYTE CORPORATION: NET SALES,
  • TABLE 122.INCYTE CORPORATION: KEY STRATERGIES
  • TABLE 123.DERMAVANT SCIENCE INC.: COMPANY SNAPSHOT
  • TABLE 124.DERMAVANT SCIENCE INC.: OPERATING SEGMENTS
  • TABLE 125.DERMAVANT SCIENCE INC.: PRODUCT PORTFOLIO
  • TABLE 126.DERMAVANT SCIENCE INC.: NET SALES,
  • TABLE 127.DERMAVANT SCIENCE INC.: KEY STRATERGIES
  • TABLE 128.VIATIRS INC. (MYLAN N.V.): COMPANY SNAPSHOT
  • TABLE 129.VIATIRS INC. (MYLAN N.V.): OPERATING SEGMENTS
  • TABLE 130.VIATIRS INC. (MYLAN N.V.): PRODUCT PORTFOLIO
  • TABLE 131.VIATIRS INC. (MYLAN N.V.): NET SALES,
  • TABLE 132.VIATIRS INC. (MYLAN N.V.): KEY STRATERGIES
  • TABLE 133.GALDERMA SA: COMPANY SNAPSHOT
  • TABLE 134.GALDERMA SA: OPERATING SEGMENTS
  • TABLE 135.GALDERMA SA: PRODUCT PORTFOLIO
  • TABLE 136.GALDERMA SA: NET SALES,
  • TABLE 137.GALDERMA SA: KEY STRATERGIES
  • TABLE 138.OBAGI COSMECEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 139.OBAGI COSMECEUTICALS LLC: OPERATING SEGMENTS
  • TABLE 140.OBAGI COSMECEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 141.OBAGI COSMECEUTICALS LLC: NET SALES,
  • TABLE 142.OBAGI COSMECEUTICALS LLC: KEY STRATERGIES
  • TABLE 143.DR. REDDY'S LABORATORIES LIMITED: COMPANY SNAPSHOT
  • TABLE 144.DR. REDDY'S LABORATORIES LIMITED: OPERATING SEGMENTS
  • TABLE 145.DR. REDDY'S LABORATORIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 146.DR. REDDY'S LABORATORIES LIMITED: NET SALES,
  • TABLE 147.DR. REDDY'S LABORATORIES LIMITED: KEY STRATERGIES
  • TABLE 148.GLENMARK PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 149.GLENMARK PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 150.GLENMARK PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 151.GLENMARK PHARMACEUTICALS LTD: NET SALES,
  • TABLE 152.GLENMARK PHARMACEUTICALS LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.PIGMENTATION DISORDER TREATMENT MARKET SEGMENTATION
  • FIGURE 2.PIGMENTATION DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 3.PIGMENTATION DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.PIGMENTATION DISORDER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.PIGMENTATION DISORDER TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF VITILIGO PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MELASMA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.PIGMENTATION DISORDER TREATMENT MARKET,BY TREATMENT,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CALCINEURIN INHIBITOR PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.PIGMENTATION DISORDER TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES PIGMENTATION DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 26.PIGMENTATION DISORDER TREATMENT MARKET BY REGION,2021
  • FIGURE 27.U.S. PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.UK PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.CHINA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.INDIA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.ARCUTIS BIOTHERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 53.ASTELLAS PHARMA INC..: NET SALES ,($MILLION)
  • FIGURE 54.BAUSCH HEALTH COMPANIES INC.: NET SALES ,($MILLION)
  • FIGURE 55.INCYTE CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 56.DERMAVANT SCIENCE INC..: NET SALES ,($MILLION)
  • FIGURE 57.VIATIRS INC. (MYLAN N.V.).: NET SALES ,($MILLION)
  • FIGURE 58.GALDERMA SA.: NET SALES ,($MILLION)
  • FIGURE 59.OBAGI COSMECEUTICALS LLC.: NET SALES ,($MILLION)
  • FIGURE 60.DR. REDDY'S LABORATORIES LIMITED.: NET SALES ,($MILLION)
  • FIGURE 61.GLENMARK PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
目次
Product Code: A11229

The global pigmentation disorder treatment market was valued at $799.79 million in 2021, and is estimated to reach $1,220.91 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031.

Pigmentation disorder is abnormality in the skin tissues, which can be diagnosed, evaluated, and treated in primary care practices. Skin color is caused by the melanin pigment. Melanocytes, a type of skin cell, produces it. Disorders of skin pigmentation can be brought on by a variety of medical conditions. Melasma, dark skin, and vitiligo are a few particular disorders that can result in skin discoloration. Vitiligo, pityriasis alba, tinea versicolor, and post inflammatory hypopigmentation are all conditions of hypopigmentation.

One of the major factors that drives the growth of the pigmentation disorder treatment market is increase in prevalence of pigmentation disorders. For instance, according to IP Indian Journal of Clinical and Experimental Dermatology published in January 2022, India is considered to have highest prevalence of vitiligo about 8.8%. In addition, increase in healthcare spending, rise in number of clinical research and product approvals contribute toward the global market growth. For instance, in July 2022 Incyte Corporation got approval from U.S. Food and Drug Administration (FDA) for its Opzelura (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Furthermore, increase in the effort for pigmentation healthcare and rise in awareness about health problems are expected to drive the market growth. However high cost associated with the treatment is expected to hinder the market growth. Conversely, increase in healthcare expenditure is another factor expected to create lucrative opportunities for market growth during the forecast period

The pigmentation disorder treatment market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is categorized into vitiligo, melasma and others. The vitiligo segment is further classified as segmental and non-segmental. By treatment, it is divided into corticosteroids, calcineurin Inhibitor, and others. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are Arcutis Biotherapeutics, Inc, Astellas Pharma Inc., Bausch Health Companies Inc, Dermavant Sciences Inc, Dr. Reddy,s Laboratories Ltd, Galderma S.A, Glenmark Pharmaceuticals Limited, Incyte Corporation, Obagi Cosmeceuticals LLC and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pigmentation disorder treatment market analysis from 2021 to 2031 to identify the prevailing pigmentation disorder treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pigmentation disorder treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pigmentation disorder treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Vitiligo
    • Type
    • Segmental
    • Non-segmental
  • Melasma
  • Others

By Treatment

  • Corticosteroids
  • Calcineurin inhibitor
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Arcutis Biotherapeutics
    • Astellas Pharma Inc.
    • Bausch Health Companies Inc
    • Incyte Corporation
    • Dermavant Science Inc.
    • Viatirs Inc. (Mylan N.V.)
    • Galderma SA
    • Obagi Cosmeceuticals LLC
    • Dr. Reddy's Laboratories Limited
    • Glenmark Pharmaceuticals Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Vitiligo
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Vitiligo Pigmentation Disorder Treatment Market by Type
      • 4.2.4.1 Segmental Market size and forecast, by region
      • 4.2.4.2 Non-segmental Market size and forecast, by region
  • 4.3 Melasma
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Corticosteroids
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Calcineurin inhibitor
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug store and retail pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: PIGMENTATION DISORDER TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
      • 7.2.2.1 North America Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.2.3 North America Market size and forecast, by Treatment
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Treatment
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Treatment
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Treatment
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
      • 7.3.2.1 Europe Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.3.3 Europe Market size and forecast, by Treatment
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Treatment
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Treatment
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Treatment
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Treatment
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Treatment
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Treatment
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
      • 7.4.2.1 Asia-Pacific Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Treatment
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Treatment
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Treatment
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Treatment
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Treatment
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Treatment
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Treatment
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
      • 7.5.2.1 LAMEA Vitiligo Pigmentation Disorder Treatment Market by Type
    • 7.5.3 LAMEA Market size and forecast, by Treatment
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Treatment
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Treatment
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Treatment
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Treatment
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Arcutis Biotherapeutics
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Astellas Pharma Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Incyte Corporation
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Dermavant Science Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Viatirs Inc. (Mylan N.V.)
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Galderma SA
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Obagi Cosmeceuticals LLC
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Dr. Reddy's Laboratories Limited
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Glenmark Pharmaceuticals Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments